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Summary
Background: Pompe disease is a rare metabolic disorder caused by a deficiency of
the lysosomal enzyme acid a-glucosidase. Glycogen accumulation damages skeletal,
cardiac, and smooth muscles, causing a progressive and debilitating muscle weak-
ness and cardiomyopathy. As life expectancy has much improved since the introduc-
tion of enzyme replacement therapy an increasing number of patients are referred
for surgical procedures. Due to the potential cardiopulmonary complications, these
patients form a high-risk group for the anesthesiologist.
Aims: In this study, we investigated the incidence of perioperative complications in
children with Pompe disease treated in our hospital since the introduction of
enzyme replacement therapy.
Methods: Anesthetic and perioperative data of children with Pompe disease trea-
ted between 1999 and 2015 in the Erasmus MC—Sophia Children’s Hospital,
University Medical Centre, Rotterdam, The Netherlands, were collected, retrospec-
tively.
Results: Of the 65 children with Pompe disease, 34 patients underwent in total
77, mostly low-risk, surgical procedures. Twenty-one children had the classic
infantile form and 13 had a nonclassic presentation of Pompe disease. In 13
(16.8%) procedures, 1 or more perioperative complications occurred. Periopera-
tive desaturation was the main complication (12.9%), followed by arrhythmia
(3.8%) and heart failure requiring diuretic treatment (2.6%). One child died
2 days postoperatively, but this was considered unrelated to the procedure.
Conclusion: Despite the potentially high anesthetic risk for children with Pompe
disease under enzyme replacement therapy, the incidence of perioperative complica-
tions in our study was relatively low. Our data suggest that with proper precaution-
ary measures and a critical choice of timing of the operation, general anesthesia in
children with Pompe disease could be relatively safe nowadays.
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1 | INTRODUCTION
Pompe disease is a metabolic myopathy or lysosomal storage disorder
caused by an inheritable deficiency of the lysosomal enzyme acid a-
glucosidase. Glycogen accumulates progressively in the lysosomes
and causes damage to myocytes. Pompe disease presents as a clinical
spectrum with a predicted frequency of 1:40 000. The classic infan-
tile form of Pompe disease (1:138 000), represents the most severe
end of the spectrum with generalized hypotonia, cardiomyopathy,
and respiratory insufficiency as characteristic features. Without
enzyme replacement therapy (ERT), these children rarely survive
beyond 1 year of age due to cardiorespiratory failure. Patients with
nonclassic presentations (1:57 000) may present at any age from
early infancy to late adulthood and the course may vary widely.1-3
Symptoms relate to skeletal and respiratory muscle weakness and
most of the patients become wheelchair bound or dependent on a
respirator at some time in life. Since the diaphragm is also involved
pulmonary function in supine position is mostly lower than in upright
position. In these patients, the heart is rarely involved.4
The worldwide introduction of ERT with recombinant human
acid a-glucosidase in 2006 has altered life expectancy substantially,
providing a therapeutic option for this previously untreatable dis-
ease.5,6 One of the consequences is that these patients are increas-
ingly eligible for surgical procedures, not only procedures related to
the disease (insertion of a Port-a-Cath [PAC] for ERT or muscle
biopsy) but also common elective surgical and diagnostic proce-
dures. However, its implications for perioperative and anesthesia
practice are largely unknown. To date, the anesthetic literature on
Pompe disease is limited and knowledge is mainly based on small
case series and case reports.7-10 In children with the classic infantile
form of Pompe disease, fatal perioperative cardiac complications,
related to cardiomyopathy, have been described.7-9 The heart is
rarely affected in children with nonclassic presentations.11 In addi-
tion, serious pulmonary complications due to respiratory muscle
weakness, such as repeated (silent) aspiration and prolonged ventila-
tion, are mentioned for both forms of Pompe disease.12-14 Bulbar
weakness leading to dysphagia as described in both children and
adults may also contribute. According to a long-term study in chil-
dren with classic infantile form of disease receiving ERT, these chil-
dren suffer from facial muscle weakness, reduced pharyngeal and
laryngeal sensibility, and dysphagia, making them more vulnerable
for postoperative aspiration.15,16
Enzyme replacement therapy was introduced in the Erasmus
MC—Sophia Children’s Hospital, University Medical Centre, Rotter-
dam, The Netherlands, already in 1999 as part of the first clinical
trial performed, applying recombinant human a-glucosidase produced
in milk of transgenic rabbits.5
In this article, we provide an overview of our anesthetic experi-
ence in children with Pompe disease since the introduction of ERT
in our hospital. We investigated the incidence of perioperative com-
plications and risk factors making a separation between patients with
classic and nonclassic presentations, and attempted to make a
recommendation regarding the anesthetic and perioperative manage-
ment of children with Pompe disease.
2 | MATERIALS AND METHODS
This retrospective cohort study investigated all children diagnosed and/
or treated with Pompe disease in the Erasmus MC—Sophia Children’s
Hospital, University Medical Centre, Rotterdam, The Netherlands,
between 1999 (introduction of ERT in our hospital) and 2015. The med-
ical charts of all Pompe patients who underwent a surgical or diagnostic
procedure under anesthesia in this period were screened for general
parameters, cardiac status, respiratory status, motor function tests, peri-
operative parameters, and adverse events. As some patients underwent
more than 1 procedure, the analysis has been done on procedure level,
with the patient status at the time of every procedure.
General parameters like age at diagnosis, age at time of the pro-
cedure, comorbidity, form of disease (classic infantile or nonclassic
presentation), and gender were collected. Also age of starting ERT
and length of treatment with ERT by the time of the first procedure
were collected, as a short duration of ERT and consequently a
potential high left ventricular mass index are related to severe car-
diomyopathy and hypothetically a higher incidence of cardiac compli-
cations during anesthesia.7,17
Cardiac status included parameters from cardiac history, physical
examination, and echocardiography to record the severity of
patients’ cardiomyopathy. Systolic function was categorized in nor-
mal, moderate, or severely affected as described in the echocardio-
graphic report. Ventricular hypertrophy was divided into 4
categories: normal, mild, moderate, or severely affected. Left ventric-
ular mass index was measured in Boston z score and BSA/Haycock
What is already known
• Children with Pompe disease are nowadays treated with
recombinant human acid a-glucosidase, which has
improved life expectancy substantially, making these
patients increasingly eligible for surgical procedures under
general anesthesia. However, implications for periopera-
tive practice are largely unknown.
What this study adds
• With adequate ERT by peripheral infusion to reduce left
ventricular mass, before undergoing an elective procedure
under general anesthesia, and with a thorough preopera-
tive evaluation of the child’s cardiac and pulmonary sta-
tus by a multidisciplinary team, anesthesia in children
with Pompe disease can be performed relatively safe
nowadays.
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according to local standards. For all parameters, time from investiga-
tion to surgical procedure was documented.
Respiratory status included reports of a polysomnography, if avail-
able. Important parameters were number of desaturations per hour,
desaturation index, apnea index, mean oxygen saturation level, and
highest carbon dioxide level (normal <52 mm Hg). Spirometry parame-
ters, in sitting and supine position, were included in the database if
available. It was documented if patients were dependent on perma-
nent or intermittent home ventilation or additional oxygen supply.18
Motor function tests included Alberta Infant Motor Score, Bayley
Scales of Infant Development second edition, and Quick Motor
Function Scale Test (QMFS%).19
Perioperative parameters included the anesthetic technique used
(local or general), medication for induction and maintenance of anes-
thesia (intravenous or inhalational), duration of induction, procedure
and recovery, type of monitoring, and postoperative destination
(ward or intensive care unit, ICU).
Adverse events were divided into 3 groups: cardiac complications
related to the cardiomyopathy (cardiac arrest, ECG ST changes,
arrhythmias, signs of heart failure), respiratory complications related
to respiratory muscle weakness (desaturation <90%, prolonged venti-
lation, prolonged neuromuscular blockade, aspiration), and general
complications (anaphylaxis, difficult airway management). If applica-
ble, the time of occurrence in the perioperative process (preopera-
tive, perioperative, postoperative) was categorized, as were
unexpected ICU admissions postoperatively.
2.1 | Statistics
Categorical data are described as counts and percentages. Continu-
ous variables are described as medians and interquartile ranges. The
relation of influencing factors and occurrence of perioperative com-
plications were analyzed using the Mann-Whitney U and chi-square
test. Data were collected and analyzed using IBM SPSS Statistics 22
(IBM Inc., Chicago, IL, USA).
3 | RESULTS
3.1 | General parameters
Sixty-five patients with Pompe disease were diagnosed and/or trea-
ted in the Erasmus MC—Sophia Children’s Hospital, Rotterdam, the
Netherlands, between February 1999 until January 2015. During
this period, 31 patients had no indication to undergo a procedure
requiring anesthesia and were therefore excluded. Our final study
sample consisted of 34 children who underwent 1 or more surgical
or diagnostic procedures, mostly low risk (Table 1). Twenty-one
(61.7%) of these children had the infantile form and 13 (38.3%)
were children with nonclassic presentations. These 34 children
underwent in total 77 procedures: 48 (62.3%) in children with
infantile form and 29 (37.7%) in the others. All except 1 child,
started to receive ERT at some point during the study period. Six
patients with the classic infantile form of disease and 10 children
with nonclassic presentations underwent the first procedure before
starting ERT (Table 2).
3.2 | Perioperative parameters
Of the 77 procedures, 71 were performed under general anesthesia.
Six were performed with a local anesthesia technique: 5 diagnostic
muscle biopsies with awake caudal anesthesia (2 of these procedures
were combined with a local anesthesia for a PAC insertion) and 1
single PAC insertion under local anesthesia. One patient with non-
classic presentation of disease had a tendon release of the foot
under general anesthesia, unfortunately exact intraoperative informa-
tion was missing.
In both forms of Pompe disease, intravenous (IV) induction of
anesthesia with propofol was most common. Three children with
classic infantile type of disease (6.3%) and 1 child with nonclassic
presentation (3.4%) had an induction with ketamine. For mainte-
nance of anesthesia, IV anesthesia with propofol (dose range 3-
15 mg/kg/h) was used more commonly in both forms of Pompe dis-
ease (Table 3).
Over the years we found a change in the anesthesia technique
used. All procedures under local anesthesia took place during the
first years (1999-2004) after introduction of ERT. During this period,
IV induction of anesthesia was the most used technique in children
with both forms of disease.
This gradually shifted to an increased use of inhalational anes-
thesia in the period from 2010 to 2015 (Figure 1A). This trend was
seen as well for maintenance of anesthesia in both forms of Pompe
disease (Figure 1B). There was no difference in incidence of
adverse events with the change in anesthetic technique. In 17 of
77 procedures, muscle relaxants were used (22.1%). None of the
children had a prolonged duration of neuromuscular block or
delayed extubation.
TABLE 1 Type of surgical procedures
Type of procedure N (%)
Insertion/Revision PAC 43 (55.8)
Insertion PAC & Muscle biopsy 9 (11.7)
Muscle biopsy 7 (9.1)
Insertion PEG 5 (6.5)
Tendon release extremity (foot) 4 (5.2)
Tracheostomy 3 (3.9)
Insertion tympanic membrane tubes 1 (1.3)
Correction eye lid 1 (1.3)
Nissen fundoplication 1 (1.3)
MRI 1 (1.3)
Laryngoscopy 1 (1.3)
Scoliosis correction 1 (1.3)
Total 77 (100)
MRI, magnetic resonance imaging; PAC, Port-a-Cath; PEG, percutaneous
endoscopic gastrostomy.
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3.3 | Adverse events
Table 4 shows the adverse events that occurred perioperatively.
One or more adverse events occurred in 13 procedures (16.8%):
in 9 (18.8%) procedures in children with the classic infantile
form, and in 4 (13.8%) children with nonclassic presentation of
disease. Desaturation <90% was the most frequent adverse
event in both groups (12.9%), occurring both during anesthesia
and postoperatively. Also cardiac arrhythmias occurred in both
groups (3.8%). In 2 cases, the occurrence of atrial extra systoles
was related to insertion of a PAC and was self-limiting by with-
drawal of the mechanical stimulus. One child suffered from a
bradycardia of 20 beats per minute intraoperatively, with an
adequate reaction to atropine. Exact duration of hemodynamic
instability could not be retrieved from written anesthetic record-
ings. Diuretic treatment because of signs of perioperative heart
failure was needed in 2 children with classic infantile form of
disease (2.6%). One child with classic infantile form presented in
the hospital, at the age of 7 months, with a very severe
TABLE 3 Anesthetic technique (procedure level)
Total
(N = 77)
Classic
infantile
disease
(N = 48)
Nonclassic
presentation
of disease
(N = 29)
Local anesthesia, n (%) 6 (8) 5 (10) 1 (3.5)
General anesthesia, n (%) 71 (92)a 43 (90) 28 (96.5)
Induction of anesthesiaa
Inhalation induction, n (%) 24 (34) 19 (44) 5 (19)
Intravenous induction, n (%) 46 (66) 24 (56) 22 (81)
Maintenance of anesthesiaa
Inhalation, n (%) 25 (36) 17 (40) 8 (30)
Intravenous, n (%) 40 (57) 22 (51) 18 (67)
Combination inhalation/IV, n (%) 5 (7) 4 (9) 1 (3)
aMissing data for 1 procedure for a patient with nonclassic presentation
of disease, who had general anesthesia. The exact choice of anesthetic
agents is missing.
TABLE 2 Key parameters of the patients with both types of
Pompe disease (patient level)
Classic infantile
disease (N = 21)
Nonclassic
presentation
of disease
(N = 13)
Number procedures
per patient
2 (1-4) 2 (1-3)
Sex (M/F, %) 10/11 (47.6/52.4%) 7/6 (53.8/46.2%)
Age 1st procedure (mo) 7 (4.5-8.0) 132 (28.5- 157.5)
ERT (%)a 21 (100%) 12 (92%)
Age start ERT (mo) 4 (1-7) 143 (44-152)
Start ERT—1st
procedure (mo)
3 (0-6.5)b 7 (1-35)c
Cardiac status
LV mass
index/BSA/(g/m2)
during first procedured
56.9 (37.6-106.5) 64 (49-81)e
Data are represented as median with 25th and 75th percentile for con-
tinuous variables.
aNumber (%) of patients starting ERT during study period.
bSix patients did not start ERT by the time of the 1st procedure.
cTen patients did not start ERT by the time of the 1st procedure.
dNormal value <95 g/m2 female, <115 g/m2 male.
eMissing data in 2 patients.
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F IGURE 1 A, Technique used for induction of general
anesthesia, 5-y interval (procedure level). Missing data for 1
procedure for a patient with nonclassic presentation of disease,
who had general anesthesia in 2009. The exact choice of
anesthetic agents is missing. B, Technique used for maintenance of
general anesthesia, 5-y interval (procedure level). Missing data for 1
procedure for a patient with nonclassic presentation of disease,
who had general anesthesia in 2009. The exact choice of
anesthetic agents is missing. Five procedures are not included in
this figure, because a combination of inhalation and IV
maintenance was used (2 procedures in 2005-2009 and 3
procedures in 2010-2015)
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cardiomyopathy, too advanced for a positive response on ERT,
due to the late diagnosis. This child had general anesthesia with
induction with ketamine and maintenance with sevoflurane to
perform a diagnostic muscle biopsy. Two days after the opera-
tion the child died of respiratory failure. Because of the poor
condition of the child, it was chosen not to initiate artificial ven-
tilation. For this reason, the outcome is considered to be unre-
lated to the operation or perioperative management.
We compared for both forms of disease the groups with
and without perioperative complications for several relevant
parameters, (such as age at start of ERT, cardiac and respiratory
status, anesthesia technique used) to determine a possible risk
factor for perioperative adverse events (Table 4). However, we
could not demonstrate any relationship between these parame-
ters and the occurrence of adverse events in both groups. The
study sample was too small for a reliable and definite statistical
analysis.
4 | DISCUSSION
The purpose of this study was to determine the incidence and sever-
ity of perioperative complications for children with Pompe disease,
undergoing anesthesia for surgical or diagnostic procedures and to
identify possible predictive factors for poor outcome. This retrospec-
tive investigation demonstrated that in 18.8% of procedures in chil-
dren with the classic infantile form of disease, 1 or more adverse
events occurred. For children with nonclassic presentations, this was
the case in 13.8% of procedures.
Given the respiratory muscle weakness in children with Pompe
and the severe cardiomyopathy in children with classic infantile
type of disease, we expected to find more complications. Litera-
ture about Pompe disease and anesthesia is limited, but the case
series and reports available show serious anesthetic complica-
tions.7-9 The fact that during the first years of our study (1999-
2004), the anesthetic record was still written manually, instead of
TABLE 4 Perioperative complications (procedure level)
Classic infantile disease
(N = 48)
Nonclassic presentation of disease
(N = 29)
Complication Yes No Yes No
Number of procedures 9 39 4 25
Age of start ERT (mo) 3 (2-6.5) 4 (1-7) 16 (12-31.2) 147.5 (126-153)
ERT not started during procedure 1 5 1 9
ERT ≤3 mo during procedure 3 6 1 1
ERT > 3 mo during procedure 5 28 2 15
Total length of ERT 4 (2-69) 7 (3-28) 17 (1-93.8) 15.5 (0-58.8)
Intermittent or permanent home ventilation (n) 2 13 0 6
Moderate or severe systolic dysfunction (n)a 1 2 0 0
Moderate or severe LV hypertrophy (n)b 6 21 0 0
Enzyme replacement therapy ERT+ ERT ERT+ ERT
Total number of complications 12 2 4 0
Number of procedures with one or more complications 8 1 4 0
Cardiac complications 3 1 1 0
Arrhythmiac 2 0 1 0
Signs of heart failure requiring diuretic treatment 1 1 0 0
Maintenance of anesthesia 0 1 0 0
<24 h postoperatively (on ICU or PACU) 1 0 0 0
Respiratory complications 9 0 3 0
Desaturation >90% 9 0 0 0
Induction of anesthesia 1 0 0 0
Maintenance of anesthesia 2 0 1 0
<24 h postoperatively (on ICU or PACU) 6 0 2 0
Other complications
Death (<30 d after operation) 0 1 0 0
Data are represented as median with 25th and 75th percentile for continuous variables.
aIn 1 patient with nonclassic presentation of disease, data are missing or investigation not performed.
bIn 1 patient with nonclassic presentation of disease, data are missing or investigation not performed.
cAll arrhythmias occurred intraoperatively.
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parameters being automatically processed on the computer, may
have caused underreporting of adverse events. Also, most surgical
procedures were low-risk procedures such as PAC insertion or
muscle biopsies. Only a few patients underwent more extensive
surgery, such as scoliosis correction or Nissen fundoplication. This
may explain the lower incidence of perioperative complications as
well.
The most common complication was a period of perioperative
desaturation <90%. In Pompe disease, there is a disproportionate
involvement of the diaphragm, which causes a reduced forced
vital capacity especially in the supine position. For this reason, it
is extremely important to perform spirometry in both sitting and
supine position in older children (above 6 years of age) and/or
perform a preoperative polysomnography in the younger ones.
Children with classic infantile form of disease with severe car-
diomyopathy may also have lung lobar collapse from cardiac com-
pression of the airway. Many patients, both with classic and
nonclassic presentations, become (partly) dependent on mechanical
ventilator support as disease progresses. Respiratory failure is a
major cause of death. Bulbar weakness may also occur in all chil-
dren with Pompe disease, but particularly in children with classic
infantile form of disease, this may cause an increased risk of aspi-
ration. Therefore, desaturation could indeed be expected perioper-
atively, and also other respiratory complications, such as prolonged
postoperative ventilation or respiratory insufficiency after extuba-
tion.14,17 We advocate to focus on these aspects prior to the ini-
tiation of an anesthetic procedure.
Also in healthy children, respiratory complications are the most
common adverse events during general anesthesia. A study in 9297
children undergoing surgery, showed an incidence of 15% respiratory
adverse events perioperatively.20 In 10% of the children, a period of
desaturation <95% was described. The incidence of perioperative
desaturation for children with Pompe disease in this study is higher
than in the general pediatric population, even when a different defi-
nition of desaturation is taken into account (<90% vs 95%). In our
study, the period of desaturation had no further implications for
treatment.
Excessive accumulation of glycogen within the lysosomes of
many tissues, including cardiac muscle cells, leads to a progressive
cardiomyopathy in children with the classic infantile form of Pompe
disease.3,4 At the time of diagnosis, a severe cardiomyopathy and
cardiac failure is present in most children, generating a high risk on
the occurrence of anesthetic complications. In children with nonclas-
sic presentations, the heart is sporadically affected.13 A noncompli-
ant left ventricle predisposes a patient to diastolic heart failure, an
elevated left ventricular end diastolic pressure and common develop-
ment of systolic heart failure.7-9 Glycogen accumulation can also be
situated in the cardiac conduction system, leading to abnormal con-
duction velocities.21 The combination of factors makes children with
the classic infantile form of disease especially vulnerable to develop
a ventricular and supraventricular tachycardia. This fragile balance
represents a challenge for a safe anesthetic procedure. In the current
study, we found cardiac arrhythmias in 2 children with classic infan-
tile form of disease and in 1 child with nonclassic form of disease. In
2 cases, the arrhythmia was probably related to the insertion of a
PAC. Ing et al described a case series of 5 children with the classic
infantile form, undergoing a total of 13 anesthetics. During one of
these procedures, a cardiac arrest occurred, followed by a successful
defibrillation procedure. In 2 cases, ST-segment depression occurred,
normalizing after administration of phenylephrine.9 Wang et al
screened 139 patients with Pompe disease for adverse events during
anesthesia. They describe 9 patients experiencing serious cardiac
arrhythmia or arrest soon after induction of anesthesia. This article
suggests an association between LV mass indices and mortality risk,
as a LV mass index >350 g/m2 was associated with death in chil-
dren with classic infantile form of disease.7 In our study none of the
children had LV mass indices in this range when undergoing anesthe-
sia.
In the study of Ing et al,9 all complications occurred in the group
of children who were not on ERT. The exact duration of ERT at the
time of the anesthesia was not mentioned in the article of Wang
et al.7 In our study, the median time of ERT before the first anesthe-
sia in children with classic infantile type of disease was 3 months, as
most of the children were given ERT by peripheral infusion before
undergoing a PAC insertion under anesthesia. One of the most
important reasons to start ERT first on a peripheral infusion and to
insert a PAC later was to increase the stability of the child first, prior
to any (elective) intervention requiring general anesthesia. During
the first 3 months of treatment, we monitor cardiac hypertrophy
and function on a monthly basis and every 3 months thereafter.14-22
Once the risk of cardiac and respiratory failure seems reduced,
general anesthesia is considered.
Other factors that may have contributed to a better outcome is
that we focus on potential signs and symptoms of bulbar muscle
weakness, respiratory difficulties, and infections which may increase
the risk of aspiration.15 Preoperative polysomnography is performed
when there are doubts. In older children, spirometry in sitting and
supine position is performed. All of these measures probably provide
an important explanation of our relatively low percentage of compli-
cations. Also the fact that children receive a higher dose of ERT in
our hospital may have contributed to a better preoperative stabil-
ity.23
We did not find a relation with anesthetic technique used
and complication rate. From the sparse available literature on
anesthesia in children with classic infantile form of disease, the
common sense is that additional care in maximizing coronary per-
fusion pressure and minimizing arrhythmia risk must be given. For
these reasons, it was recommended to avoid propofol or high
concentrations of sevoflurane. In other studies, agents such as
ketamine and etomidate were advised as the cornerstone for
induction in order to better support coronary perfusion pressure
and to avoid decreasing diastolic blood pressure with vasodilatory
agents.7-9 However, since the introduction of ERT and with chil-
dren in a physically better condition, propofol and sevoflurane
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were used in our hospital to anesthetize children with Pompe dis-
ease. The results of our study suggest that these anesthetic
agents can be used safely in children with Pompe on ERT pro-
vided that a careful preoperative workup has taken place. Keta-
mine and etomidate, or the use of a local anesthetic
technique still should be considered in children with severe
cardiomyopathy.24,25
5 | CONCLUSIONS
The purpose of this study was to determine the incidence and
severity of perioperative complications for children with Pompe dis-
ease, and to identify predictive factors for poor anesthetic out-
come. One child with classic infantile form of disease who had a
fatal clinical condition on admission, died 2 days postoperatively,
but this was probably unrelated to the general anesthesia. The
other perioperative respiratory and cardiac complications found in
this study were generally mild. Based on the experience of our
hospital and the results of this study, a multidisciplinary approach
is strongly advised, with a close cooperation between pediatric
anesthesiologists and pediatricians with experience in treating chil-
dren with Pompe disease. Any elective procedure under general
anesthesia should be postponed until the child has received ade-
quate ERT by peripheral infusion and cardiac hypertrophy is
reduced to an acceptable level and consequently arrhythmic risk.
With this standard of treatment with ERT, and a thorough preoper-
ative cardiac analysis in children with classic infantile form of dis-
ease (ultrasound, ECG) and pulmonary workup in both forms of
disease (polysomnography, and if possible sitting and supine
spirometry) to assess respiratory risk, anesthesia may be relatively
safe. A multidisciplinary approach and close cooperation between
pediatricians, pediatric surgeons, and pediatric anesthesiologists is
essential for timing of the surgical procedure, deciding on the best
anesthesiologic treatment and perioperative care for the individual
patient.
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